Inotiv, Inc. (NASDAQ:NOTV – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2023 EPS estimates for Inotiv in a research note issued on Thursday, January 19th. Jefferies Financial Group analyst D. Windley anticipates that the company will earn ($0.44) per share for the quarter. Jefferies Financial Group currently has a “Hold” rating and a $8.00 target price on the stock. The consensus estimate for Inotiv’s current full-year earnings is $1.57 per share. Jefferies Financial Group also issued estimates for Inotiv’s Q2 2023 earnings at $0.04 EPS, Q3 2023 earnings at $0.29 EPS and Q4 2023 earnings at $0.46 EPS.
Other analysts also recently issued research reports about the stock. TheStreet downgraded shares of Inotiv from a “c-” rating to a “d+” rating in a report on Wednesday, November 9th. Lake Street Capital upgraded shares of Inotiv from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Wednesday, January 11th. Finally, Craig Hallum decreased their price target on shares of Inotiv from $64.00 to $34.00 in a research note on Wednesday, January 11th.
Inotiv Stock Performance
Hedge Funds Weigh In On Inotiv
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NOTV. ClariVest Asset Management LLC raised its holdings in Inotiv by 52.2% during the 2nd quarter. ClariVest Asset Management LLC now owns 30,900 shares of the company’s stock valued at $297,000 after acquiring an additional 10,600 shares during the period. Ophir Asset Management Pty Ltd boosted its stake in Inotiv by 6.8% in the 2nd quarter. Ophir Asset Management Pty Ltd now owns 1,125,473 shares of the company’s stock worth $8,193,000 after purchasing an additional 71,377 shares during the period. King Luther Capital Management Corp grew its holdings in Inotiv by 78.9% during the 3rd quarter. King Luther Capital Management Corp now owns 113,340 shares of the company’s stock valued at $1,910,000 after buying an additional 50,000 shares in the last quarter. Invenire Partners LP bought a new stake in shares of Inotiv during the third quarter valued at about $1,601,000. Finally, Jump Financial LLC lifted its holdings in shares of Inotiv by 22.1% in the third quarter. Jump Financial LLC now owns 31,200 shares of the company’s stock worth $526,000 after buying an additional 5,640 shares in the last quarter. Institutional investors own 52.04% of the company’s stock.
Inotiv Company Profile
Inotiv, Inc operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing.
- Get a free copy of the StockNews.com research report on Inotiv (NOTV)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.